The abstract is read at the publisher; the summary is JClub's.
SPEN inactivation is linked to reduced benefit from androgen receptor pathway inhibitors in metastatic prostate cancer, with shorter time on therapy in large real-world cohorts.
- Why it matters: Biomarkers for ARPI resistance in metastatic prostate cancer are still needed to guide treatment selection beyond standard clinical factors.
- What they did: Using LNCaP and VCaP models, genome-wide loss-of-function screening, clinicogenomic database analyses (N = 6,828), and rapid-autopsy tissue microarrays (N = 181), SPEN mutations and SPEN H-score were tested against time to next treatment.
- The result: SPEN mutations are enriched after ARPI treatment (2.1%-3.6%; P = 0.001) and correlate with shorter TTNT in metastatic hormone-sensitive disease (6.4 vs. 29.7 months; HR, 2.67; P = 0.02), while low SPEN H-score predicts shorter time on abiraterone in metastatic castration-resistant disease (5 vs. 7.9 months; P = 0.023).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.